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Abstract
Background: Angiogenesis is a multistep process in which many growth factors and cytokines have an essential role. 
Vascular endothelial growth factor (VEGF) is a potent angiogenic agent that acts as a specific mitogen for vascular 
endothelial cells through specific cell surface receptors. The interleukin-6 (IL-6) pathway is another mechanism linking 
angiogenesis to malignancy. C-reactive protein (CRP), a representative marker for inflammation, is known for its 
association with disease progression in many cancer types. The aim of this study was to determine preoperative serum 
levels of VEGF, IL-6, and CRP in colorectal carcinoma, and to correlate them with disease status and prognosis.
Methods: A 132 of 143 patients who underwent curative resection for colorectal cancer were enrolled in this study. 11 
patients with resection margin positive were excluded. Factors considered in analysis of the relationship between VEGF, 
IL-6, and CRP and histological findings. Patient prognosis was investigated. Serum levels of VEGF and IL-6 were assessed 
using Enzyme-Linked Immuno-Sorbent Assay (ELISA), and CRP was measured using immunoturbidimetry.
Results: Median follow-up duration was 18.53 months (range 0.73-43.17 months) and median age of the patients was 
62 years (range, 26-83 years). Mean and median levels of VEGF and CRP in colorectal cancer were significantly higher 
than in the normal control group; 608 vs. 334 pg/mL and 528 (range 122-3242) vs. 312 (range 16-1121) (p < 0.001); 1.05 
mg/dL vs. 0.43 mg/dL and 0.22 (range 0.00-18.40) vs. 0.07 (range 0.02-6.94) (p = 0.002), respectively. However mean and 
median level of IL-6 in patients were not significantly higher than in control; 14.33 pg/mL vs. 5.65 pg/mL and 6.00 
(range 1.02-139.17) vs. 5.30 (4.50-13.78) (p = 0.327). Although IL-6 and CRP levels were not correlated with other 
pathological findings, VEGF level was significantly correlated with tumor size (p = 0.012) and CEA (p = 0.038). When we 
established the cutoff value for VEGF (825 pg/mL), IL-6 (8.09 pg/mL), and CRP (0.51 mg/dL) by Receiver Operating 
Characteristic (ROC) curve, we noted that high VEGF levels tended to reduce overall survival (p = 0.053), but not 
significantly. However, IL-6 and CRP demonstrated no significance with regard to disease free survival (p = 0.531, p = 
0.701, respectively) and overall survival (p = 0.563, p = 0.572, respectively). Multivariate analysis showed that VEGF (p = 
0.032), CEA (p = 0.012), lymph node metastasis (p = 0.002), and TNM stage (p = 0.025) were independently associated 
with overall survival.
Conclusions: Preoperative serum VEGF and CRP level increased in colorectal cancer patients. High VEGF level has been 
proposed as a poor prognostic factor for overall survival in patients with colorectal cancer.
Background
Colorectal cancer is a common malignant disease,
accounting for approximately 15% of all human cancers
[1]. In Korea, it is the third most common cancer and the
fourth cause of cancer death and its incidence is increas-
ing [2]. Incidence of colorectal cancer has grown rapidly
since 1990, and is influenced by eating and lifestyle habits
that include increased meat intake and reduced fiber
intake, alcohol consumption, and smoking. Current diag-
nostic techniques and universal colonoscopy have
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enabled relatively early diagnosis of colorectal cancer, and
the cure rate for early stage colorectal cancer is high, at
up to 80-90% [3]. Although AJCC TNM classification is
useful for staging of colorectal cancer patients and selec-
tion for specific treatment, it is not sufficient, as outcome
may vary in different patients at the same stage, indicat-
ing that conventional staging procedures may not provide
accurate prediction of cancer prognosis. Independent of
the TNM Stage, the carcinoembryonic antigen (CEA) is
used for prediction of prognosis; however, diagnostic
sensitivity of CEA is unsatisfactory. Therefore, an appro-
priate molecular marker is a necessity for adequate treat-
ment of aggressive CRC patients with adjuvant systemic
chemotherapy or targeted therapy.
Because new blood vessel formation provides a route
for spread of tumor cells to distant organs, angiogenesis
as a central process in progression of solid tumors is a
well-established aspect of cancer biology [4]. The process
may result from an imbalance between positive and nega-
tive angiogenic regulators released by both tumor cells
and host cells [5]. Tumor angiogenesis and its promoting
growth factors have been associated with advanced stage,
lymph node involvement and poor survival in a variety of
human cancers [6-8]. One of the major pathways associ-
ated with this process is that of the vascular endothelial
growth factor (VEGF) family of proteins and receptors.
Indeed, many tumor cell lines secrete VEGF in vitro, and
h i g h  V E G F  m R N A  l e v e l s  c a n  b e  d e t e c t e d  b y  i n  s i t u
hybridization in most human tumors, including lung,
breast, and gastrointestinal carcinoma [9]. Both VEFG
and its receptor are expressed at high levels in metastatic
human colon carcinomas and in tumor associated
endothelial cells, and production of these two proteins
correlates directly with degree of tumor vascularization
[10].
Interleukin-6 (IL-6) is a multipoietic cytokine produced
by many cell types. IL-6 acts on a wide range of tissues
and cell lines, and induces cell growth and differentiation,
production and expression of other cytokines, and acute-
phase protein synthesis. IL-6 also promotes growth arrest
[11,12], and promotes angiogenesis through induction of
VEGF expression [13,14].
C-reactive protein (CRP) is an acute reactant protein
that is increased under conditions of infection, trauma,
tissue necrosis, tumor, and several types of inflammatory
disease. It reflects inflammatory status and is a compo-
nent of the inflammatory response of the immune system
[15,16]. Several studies have reported that in occurrence,
progression, metastasis, and recurrence of colorectal can-
cer, systemic inflammation has an important role, and
that CRP may be a useful indicator of inflammatory
response. Results from various studies have proven that
precancerous lesions are derived from systemic inflam-
mation and local inflammation of the mucous membrane
as part of the process of cell degeneration, and that col-
orectal cancer progresses from adenoma to adenocarci-
noma [17,18].
Therefore, the objective of the current investigation is
to assess the prognostic significance of preoperative
serum VEGF, IL-6, and CRP levels as indicators of out-
come in patients with colorectal cancer.
Methods
Patients
A total of 143 patients who underwent surgery for col-
orectal cancer at Dong-A University Hospital between
December 2005 and December 2008 were enrolled in this
study. All patients had histologically confirmed adenocar-
cinoma of the colon or rectum, and a 132 of the 143 had
undergone a potentially curative resection. A 11 of the
143 patients showed microscopic evidence of residual
disease; therefore, they were excluded. The control group
consisted of 50 persons who underwent health check-ups
(25 men and 25 women; median age, 41.5 years; range, 18
to 68 years) absence of neoplastic disease was established
in these patients through laboratory testing including
serum VEGF, IL-6 and CRP levels. Staging was based on
routine postoperative histopathological analysis and clin-
ical assessment by the American Joint Committee on
Cancer (AJCC) TNM staging system. Disease status of
patients was evaluated by abdominal computed tomogra-
phy after surgery. CT was checked every 3 months for the
first 2 years, and then every 6 months for a total of 5
years. Colonoscopy was performed at 1 year after the
resection. Clinical outcomes were followed from the date
of surgery to either the date of death or July 2009. A total
of 11 colorectal cancer patients died of malignancy and 6
patients were lost during the observation period. The
median follow-up period was 18.53 months (range 0.73-
43.17). The study was approved by the Institutional
Review Board (IRB). All patients provided informed con-
sent, and the hospital review board approved the study.
Assay of serum VEGF, IL-6, and CRP
Venous blood sampling was conducted within a period of
7 days prior to surgery. Blood collected for VEGF and IL-
6 serum level assessments was collected in plain tubes,
and levels of serum VEGF and IL-6 were measured using
commercially available enzyme-linked immunosorbent
assays (ELISAs). Blood samples were centrifuged for 10
min at 3,000 r/min at -4°C. Serum was subsequently
removed and stored at -80°C for use in biochemical anal-
ysis. Blood samples for CRP analysis were collected in
serum separation tubes, and serum CRP levels were mea-
sured via immunoturbidimetry.Kwon et al. BMC Cancer 2010, 10:203
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Statistical analysis
Relationships and interactions of the prognostic factors
were tested using the Mann-Whitney U-test and the
Kruskal Wallis test. Serum levels of VEGF, IL-6, and CRP
were expressed as means and median values. VEGF, IL-6,
and CRP cut-off values for survival analysis were deter-
mined by ROC curve; 825 pg/mL, 11.68 pg/mL, and 0.185
mg/dL, respectively. Duration of recurrence of colorectal
cancer and death measured from the date of surgery was
referenced against disease free survival and overall sur-
vival time. Survival duration was calculated via the
Kaplan-Meier method. The log-rank test was employed
for comparison of cumulative survival rate and disease
free survival in the patient group. For identification of
independent factors significantly associated with patient
prognosis, we used multivariate analyses employing the
Cox proportional hazards model. A p value < 0.05 was
considered statistically significant. Variables found to be
significant at a level of p < 0.05 were considered eligible
for multivatiate regression analysis. The Statistical Pack-
age for Social Sciences (SPSS) Version 14.0 (SPSS Inc,
Chicago, IL, USA) for Windows was utilized for all statis-
tical analyses.
Results
Patients were classified according to their pathologic
characteristics, included tumor size, depth of tumor inva-
sion, status of lymph node (LN) metastasis, lymph node
ratio, CEA, American Joint Committee on Cancer tumor-
nodes-metastases (AJCC TNM) stage, sex, and age.
Patients included 79 men and 53 women, with a median
age of 62 years (range, 26-83 years). Characteristic data
for the study population are shown in Table 1. Median
follow-up duration was 19.25 months (range 0.73-43.17
months).
Mean and median levels of VEGF and CRP in the col-
orectal cancer group were significantly higher than in the
normal control group; 620 vs. 334 pg/mL and 541 vs. 312
pg/mL (p < 0.001); 1.12 vs. 0.43 mg/dL and 0.25 vs. 0.07
mg/dL (p = 0.001). However mean and median level of
IL-6 in patients were not significantly higher than in the
control group; 13.77 vs. 5.65 pg/mL and 5.74 vs. 5.30 pg/
mL (p = 0.437), respectively (Table 2).
Relationships between VEGF, IL-6, and CRP levels, and
clinicopathologic variables were tested using the Mann-
Whitney U-test and the Kruskal test. Details of these
relations are listed in Table 3. VEGF was found to be sig-
nificantly correlated with tumor size (p = 0.012) and CEA
(p  = 0.038). But no significantly correlations were
observed between VEGF and other variables. IL-6 and
CRP levels were not correlated with other pathological
findings.
The relationship between serum levels of VEGF, IL-6,
CRP, and clinicopahologic variables was evaluated using
the Kaplan-Meier method. We established the cutoff
value for VEGF (825 pg/mL), IL-6 (8.09 pg/mL), and CRP
(0.51 mg/dL) by ROC curve. Univariate log-rank analysis
showed that CEA (p < 0.001), regional lymph nodes sta-
tus (p < 0.001), tumor size (p = 0.029), and lymph node
ratio (p = 0.001) were reduced overall survival. We noted
that high VEGF levels tended to reduce overall survival (p
= 0.053, Figure 1), but not significantly. VEGF levels dem-
onstrated no significance with regard to disease free sur-
vival (p = 0.236, Figure 2). IL-6 and CRP levels provided
no significant evidence with regard to overall patient sur-
vival (p = 0.956, p = 0.607 respectively) and disease free
survival (p = 0.531, p = 0.701, respectively). Multivariate
regression analysis using Cox's proportional hazards
model revealed that VEGF (p = 0.032, HR = 4.779), CEA
(p = 0.012, HR = 7.981), regional lymph nodes status (p <
0.001), and age (p = 0.005, HR 11.91) were independent
prognostic factors for survival of colorectal cancer (Table
4).
Discussion
Recent studies have shown the correlation between tissue
VEGF expression and tumor aggressiveness in colon car-
c i n o m a .  V E G F  e x p r e s s i o n  w a s  f o u n d  t o  b e  h i g h e r  i n
patients who had metastatic tumors compared with
patients who had non-metastatic tumors [10], [19,20].
Takahashi et al [21] showed that VEGF expression level in
patients with lymph node negative colon carcinoma was
significantly associated with time of recurrence, whereas
Cascinu et al [22] confirmed that positive VEGF status
was associated with a significant reduction in 5-year DFS
rate.
The prognostic impact of serum VEGF levels in cancer
patients has been evaluated in a few studies. A large study
by Danish Colorectal Cancer Study Group found that
high preoperative VEFG concentrations were associated
with reduced overall survival with respect to patients
with colon carcinoma who had lower VEGF serum val-
ues, and suggested a biologically relevant role for serum
VEGF concentration in patients with colorectal carci-
noma [23-25].
According to findings from recent studies, VEGF has
been proposed as a potential biomarker for prediction of
colorectal cancer prognosis. De Vita et al [26] determined
preoperative and post operative serum VEGF levels by
ELISA in patients with colon cancer who underwent sur-
gery. They found that preoperative VEGF was signifi-
cantly higher in the colon cancer compared with the
control group, and preoperative VEGF was significantly
lower in patients who underwent curative surgery com-
pared with patients who underwent non-curative surgery.
Therefore, they suggested that preoperative serum VEGF
levels might be useful for prediction of outcome in
patients with colon cancer who underwent surgery.Kwon et al. BMC Cancer 2010, 10:203
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Another study investigated VEGF expression in colorec-
tal cancer specimens by performance of immunohis-
tochemistry on tissue microarrays [27]. In that study, the
authors found VEGF expression in all tumors evaluated;
they also found greater intensity of VEGF staining,
greater lymph node metastasis, higher stage, and poorer
disease-specific survival. They concluded that VEGF
expression in colorectal cancer appears to be an indepen-
dent prognostic marker of tumor behavior, and that it
may be useful in identification of patients with unfavor-
able clinical outcome.
In our study, preoperative serum VEGF level by ELISA
in the patient group was significantly higher than levels in
the control group (p  < 0.001) and preoperative serum
VEGF levels were significantly correlated with CEA levels
(p = 0.038) and tumor size (p = 0.012). When we estab-
lished the cutoff value for VEGF (825 pg/mL) by ROC
curve, we noted that high VEGF levels tended to reduce
overall survival, but was not significantly (p = 0.053). No
significant correlation was found between VEGF preop-
erative levels and disease stage, gender, tumor depth, and
status of lymph node metastasis.
Currently, ample literature is available with regard to
the role of various cytokines in colorectal cancer patients.
Mechanisms leading to IL-6 induction and to IL-6 pres-
ence in high concentrations in the serum of those
patients include CEA-induced IL-6 production by
Kupffer cells, malignancy-related chronic stress leading
to increased IL-6 blood concentrations, as well as direct
IL-6 production and secretion by tumor-associated mac-
rophages or the tumor cells themselves. According to
some studies that evaluated clinical significance of IL-6
pre-treatment levels, IL-6 concentrations reflected dis-
ease status, and were commonly associated with meta-
static disease [28,29]. Findings from other research did
not reveal a significant association between IL-6 and
tumor stage, or other clinical findings [30]. However, the
authors of that study found significant correlation
between large tumor size and hepatic metastasis corre-
lated with elevated IL-6 levels significantly. Furthermore,
high IL-6 levels were associated with reduced overall sur-
Table 1: Patient characteristics
No. of patients %
Total number of patients 132
Sex
Male 79 59.8
Female 53 40.2
Median age(range) 62(26-83)
<60 52 39
≥60 80 61
CEA
≤5 ng/mL 99 75.6
>5 ng/mL 32 24.4
Tumor size
<5 cm 58 43.9
≥5 cm 74 56.1
Lymph node ratio
pNr1 0.01-0.11 103 78
pNr2 0.12-0.24 17 12.9
pNr3 0.25-0.92 12 9.1
Primary Tumor
pT1 12 9.1
pT2 19 14.4
pT3 90 68.2
pT4 11 8.3
Regional Lymph nodes
N0 75 56.8
N1 36 27.3
N2 21 15.9
Differentiation
Well 67 50.8
Moderate 52 39.4
Poor 5 3.8
Mucinous 8 6.1
TNM stage
Stage I 27 20.5
StageII 48 36.4
StageIII 57 43.2
CEA: carcinoembryonic antigen, normal range 0-5 ng/mL
Table 2: The mean and median levels of VEGF, IL-6 and CRP in colorectal cancer patients and control group
Patients (n = 132) Control (n = 50) P-value
Mean Median (range) Mean Median (range)
VEGF 608 528 (122-3242) 334 312 (16-1121) < 0.001
IL-6 14.33 6.00 (1.02-139.17) 5.65 5.30 (4.50-13.78) 0.327
CRP 1.05 0.22 (0.00-18.40) 0.43 0.07 (0.02-6.94) 0.002
** Range of Values (Serum); VEGF 62-707 pg/mL; IL-6 3.12-15.5 pg/mL; CRP 0-0.5 mg/dLKwon et al. BMC Cancer 2010, 10:203
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Table 3: Correlation between the IL-6, VEGF, CRP, and clinicopathological parameters
VEGF pg/ml IL-6 pg/ml CRP mg/dL
Mean Median (range) p Mean Median (range) p Mean Median (range) p
Sex
Male 656 567 (131-3242) 0048 13.12 5.03 (1.02-139.17) 0.019 1.24 0.25 (0.01-18.40) 0.827
Female 567 469 (123-2001) 16.14 7.71 (1.25-90.06) 0.83 0.16 (0.00-8.41)
Age
< 60 634 569 (123-1620) 0.363 15.31 5.61 (1.02-90.06) 0.854 1.15 0.17 (0.02-8.41) 0.610
≥ 60 593 494 (131-3242) 13.70 6.63 (1.58-139.17) 0.98 0.24 (0.00-18.40)
CEA
≤ 5 583 493 (123-32.42) 0.038 12.98 5.70 (1.02-94.11) 0.255 1.14 0.20 (0.01-18.40) 0.824
> 5 680 635 (131-1619) 18.91 8.0 (1.58-139.17) 0.80 0.25 (0.02-6.97)
Primary tumor
pT1 452 422 (123-892) 0.540 18.60 3.93 (2.18-94.11) 0.549 1.02 0.16 (0.01-6.22) 0.905
pT2 565 471 (139-1585) 14.78 7.74 (1.02-70.96) 0.67 0.33 (0.02-3.43)
pT3 639 546 (126-3242) 13.35 6.02 (1.25-139.17) 1.17 0.24 (0.00-18.40)
pT4 606 567 (174-1216) 17.00 6.05 (3.44-88.96) 0.77 0.53 (0.03-2.29)
Regional Lymph nodes
N0 652 539 (123-3242) 0.557 13.32 6.49 (1.02-94.11) 0.533 1.04 0.26 (0.01-10.09) 0.432
N1 579 562 (139-1098) 8.53 5.66 (1.49-30.02) 1.23 0.13 (0.00-18.40
N2 560 432 (156-1620) 27.92 6.31 (1.25-139.17) 0.79 0.20 (0.02-7.83)
Lymph node ratio
pNr1 0.01-0.11 634 558 (123-3242) 0.215 11.89 5.58 (1.02-94.11) 0.242 1.16 0.25 (0.0-18.40) 0.352
pNr2 0.12-0.24 495 495 (145-1619) 20.86 6.31 (1.91-90.06) 0.76 0.11 (0.00-6.97)
pNr3 0.25-0.92 446 430 (156-1068) 26.10 10.15 (1.25-139.17) 0.54 0.17 (0.04-2.18)
Size
< 5 cm 550 463 (123-3242) 0.012 10.58 5.15 (1.02-76.79) 0.129 1.32 1.15 (0.00-18.40) 0.739
≥ 5 cm 655 577 (126-2001) 12.28 7.15 (1.25-139.17) 0.84 0.25 (0.01-8.41)
Stage
Stage I 547 471 (123-1586) 0.320 17.60 5.52 (1.02-94.11) 0.907 0.88 0.16 (0.01-6.22) 0.681
Stage II 711 573 (126-3242) 10.94 10.94 (1.58-93.08) 1.13 0.28 (0.01-10.09)
Stage III 553 495 (139-1620) 15.67 5.97 (1.25-139.47) 1.07 0.13 (0.00-18.40)
Differentiation
Well 644 495 (123-3242) 0.234 12.07 5.49 (1.02-94.11) 0.275 0.75 0.25 (0.01-6.97) 0.957
Moderate 541 511 (133-1620) 18.07 7.45 (1.49-139.17) 1.60 0.15 (0.00-18.40)
Poor 531 520 (174-1083) 7.45 8.42 (2.65-11.88) 0.28 0.20 (0.00-0.54)
Mucinous 805 663 (448-1258) 13.35 8.30 (1.25-39.03) 0.52 0.18 (0.02-1.60)Kwon et al. BMC Cancer 2010, 10:203
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vival. Different from prior studies, was the fact that it was
comprised more of non-metastatic stages, which
strengthens the clinical relevance of this observation.
They suggested that in the absence of advanced meta-
static disease, IL-6 levels may be used as an adverse prog-
nostic marker.
CRP is synthesized in hepatocytes and produced by
other organs in response to release of IL-6 by monocytes
and other immune cells [31]. Increased CRP level has
been previously reported in patients with impaired T
lymphocyte response; thus this mechanism is considered
to have an association with the immune system and poor
survival rate [32]. Elevated levels of this marker of infec-
tion have been associated with increased risk of cardio-
vascular disease [33], and have been identified as a poor
prognostic factor for several diseases, including a variety
of cancers in a number of previous studies [34-37]. Find-
ings from studies in patients with colorectal cancer have
indicated that those with elevated serum CRP concentra-
tions had poorer prognoses than those whose CRP level
did not increase. In addition, it has been suggested that
increased CRP was associated with more frequent local
tumor invasion [38], more advanced pathologic stage
[39], a higher rate of recurrence [40], and reduced overall
survival [30].
Unlike results from earlier studies, we were unable to
determine the correlation between IL-6 and CRP and
prognostic factors. Although IL-6 and CRP levels showed
no correlation with other pathological findings, mean and
median levels of CRP in colorectal cancer patients were
significantly higher than those in normal individuals (p =
0.001). When we established the cutoff value for IL-6
(11.68 pg/mL), and CRP (0.185 mg/dL) by ROC curve, IL-
6 and CRP showed no significant evidence with regard to
disease free survival (p = 0.701, p = 0.531, respectively)
and overall survival (p = 0.563, p = 0.572, respectively).
This retrospective study had some limitations. First, the
patient group was restricted to patients who underwent
surgery. Thus this study included more patients who were
able to undergo surgery at a lower stage (not included
stage IV). And we did not consider patients who under-
went surgery or those who had any concomitant disease
suspected of raising VEGF, IL-6, or CRP (i.e., chronic
inflammatory disorders, diabetes mellitus, ischemic heart
disease, etc.). Thus, these were possible causes for misin-
terpretation of results. The most important limitation of
this study is the lack of post operative VEGF, IL-6 and
CRP levels. De Vita et al.[26] suggested preoperative
VEGF and CEA levels as good prognostic indicators for
curative and noncurative surgery, and VEGF levels
dropped significantly after surgery, with a further down-
ward trend until the 30th postoperative day. However if
we had determined postoperative serum levels of VEGF,
IL-6, and CRP, we would have been able to obtain more
information with regard to prognosis. For examples, nor-
malization of postoperative serum levels could suggest
radical surgery; serum level decrement would show
secretion of the marker by the tumor, and patients under-
going potentially curative surgery who does not show
serum level normalization of the marker should undergo
treatment with chemotherapy regardless of the TNM
stage, and increased serum levels during the follow-up
period could be prediction of recurrence.
Conclusively, high preoperative VEGF levels were asso-
ciated with tumor size, higher CEA, and VEGF was inde-
pendent of overall survival with CEA and lymph node
status. Thus we surmise that the prognosis in colorectal
Figure 1 Overall survival curve according to VEGF level.
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cancer patients with high VEGF levels would be generally
poor.
Conclusions
As a result of the current study, VEGF is suggested as an
important prognostic factor for colorectal cancer. For the
future, more prospective studies will be necessary for
investigation of predictive biomarkers for colorectal can-
cer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KAK performed the statistical analysis and drafted the manuscript. H-CK col-
lected the data, performed the statistical analysis with interpretation and criti-
cally revised the manuscript. SHK, SYO and SL performed the chemotherapy
for patients and revised the manuscript. HJC and KJP performed the opera-
tions for patients and revised the manuscript. KHK, J-YH, RYG and MSR carried
out the immunoassays. JHL and H-JK conceived of the study, and approved the
final manuscript. All authors read and approved the final manuscript.
Acknowledgements
This paper was supported by the Dong-A University Research Fund.
Author Details
1Department of Internal Medicine, Dong-A university College of Medicine, 
Busan, Korea, 2Department of Laboratory Medicine, Dong-A university College 
of Medicine, Busan, Korea, 3Department of Surgery, Dong-A university College 
of Medicine, Busan, Korea, 4Department of Pathology, Dong-A university 
College of Medicine, Busan, Korea and 5Medical Research Center for Cancer 
Molecular Therapy, Dong-A University College of Medicine, Busan, Korea
References
1. Giatromanolaki A, Sivridis E, Koukourakis MI: Angiogenesis in colorectal 
cancer: prognostic and therapeutic implications.  Am J Clin Oncol 2006, 
29(4):408-417.
2. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, 
Hwang IK, Lee DH, et al.: Nationwide cancer incidence in Korea, 2003-
2005.  Cancer Res Treat 2009, 41(3):122-131.
3. Compton CC, Greene FL: The staging of colorectal cancer: 2004 and 
beyond.  CA Cancer J Clin 2004, 54(6):295-308.
4. Folkman J: What is the evidence that tumors are angiogenesis 
dependent?  J Natl Cancer Inst 1990, 82(1):4-6.
5. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes 
as inducers of tumor angiogenesis.  Cancer Metastasis Rev 1995, 
14(4):263-277.
6. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: 
Vascular permeability factor/vascular endothelial growth factor: a 
multifunctional angiogenic cytokine.  EXS 1997, 79:233-269.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability 
factor/vascular endothelial growth factor, microvascular 
hyperpermeability, and angiogenesis.  Am J Pathol 1995, 
146(5):1029-1039.
8. Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A, 
Akagi M, Ellis LM: Biology of angiogenesis in tumors of the 
gastrointestinal tract.  Microsc Res Tech 2003, 60(2):199-207.
9. Ferrara N: Molecular and biological properties of vascular endothelial 
growth factor.  J Mol Med 1999, 77(7):527-543.
10. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of 
vascular endothelial growth factor and its receptor, KDR, correlates 
with vascularity, metastasis, and proliferation of human colon cancer.  
Cancer Res 1995, 55(18):3964-3968.
11. Van Snick J: Interleukin-6: an overview.  Annu Rev Immunol 1990, 
8:253-278.
12. Sehgal PB: Regulation of IL6 gene expression.  Res Immunol 1992, 
143(7):724-734.
13. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces 
the expression of vascular endothelial growth factor.  J Biol Chem 1996, 
271(2):736-741.
14. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, 
Theamboonlers A, Poovorawan Y: Diagnostic role of serum interleukin-
18 in gastric cancer patients.  World J Gastroenterol 2006, 
12(28):4473-4477.
15. Ballou SP, Lozanski G: Induction of inflammatory cytokine release from 
cultured human monocytes by C-reactive protein.  Cytokine 1992, 
4(5):361-368.
16. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM: C-reactive 
protein induces human peripheral blood monocytes to synthesize 
tissue factor.  Blood 1993, 82(2):513-520.
17. Law DJ, Olschwang S, Monpezat JP, Lefrancois D, Jagelman D, Petrelli NJ, 
Thomas G, Feinberg AP: Concerted nonsyntenic allelic loss in human 
colorectal carcinoma.  Science 1988, 241(4868):961-965.
18. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, 
Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during 
colorectal-tumor development.  N Engl J Med 1988, 319(9):525-532.
Received: 14 December 2009 Accepted: 14 May 2010 
Published: 14 May 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/203 © 2010 Kwon et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:203
Table 4: Multivariate analysis on OS and DFS in 143 colorectal cancer patients
DFS OS
HR 95% C.I p HR 95% C.I p
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CEA, <5 vs. ≥5 ng/mL 8.391 2.51-28.07 0.001 7.981 1.44-44.10 0.012
Tumor size, <5 vs. ≥5 cm 0.210 0.06-0.81 0.023 3.448 0.29-41.06 0.327
T, T1 vs. T2 vs. T3 vs. T4 2.479 0.94-6.57 0.068 5.963 0.76-46.87 0.090
N, N0 vs. N1 vs. N2 4.807 2.38-9.72 <0.001 5.867 2.86-86.20 0.002
Stage, I vs. II vs. III 0.783 0.12-5.10 0.798 0.042 0.00-0.67 0.025
Age, <60 vs. ≥60 0.726 0.20-2.59 0.622 11.91 2.14-66.33 0.005
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